Affordable Inactivated Poliovirus Vaccine: Strategies and Progress
After polio eradication is achieved, the use of live-attenuated oral poliovirus vaccine (OPV) must be discontinued because of the inherent risk of the Sabin strains to revert to neurovirulence and reacquire greater transmissibility that could potentially result in the reestablishment of polio transm...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2014-11, Vol.210 (suppl_1), p.S459-S464 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S464 |
|---|---|
| container_issue | suppl_1 |
| container_start_page | S459 |
| container_title | The Journal of infectious diseases |
| container_volume | 210 |
| creator | Okayasu, Hiromasa Sutter, Roland W. Jafari, Hamid S. Takane, Marina Aylward, R. Bruce |
| description | After polio eradication is achieved, the use of live-attenuated oral poliovirus vaccine (OPV) must be discontinued because of the inherent risk of the Sabin strains to revert to neurovirulence and reacquire greater transmissibility that could potentially result in the reestablishment of polio transmission. In 2008, the World Health Assembly mandated that the World Health Organization establish a strategy for developing more-affordable inactivated poliovirus vaccine (IPV) options for low-income countries. In 2012, the Strategic Advisory Group of Experts (SAGE) on Immunization recommended universal IPV introduction as a risk-mitigation strategy before the phased cessation of OPV (starting with Sabin type 2) and emphasized the need for affordable IPV options. In 2013, SAGE reiterated the importance of attaining the long-term target price of IPV at approximately $ 0.5 per immunizing dose and encouraged accelerated efforts to develop lower-cost IPV options. This article outlines the 4-pronged approach that is being pursued to develop affordable options and provides an update on the current status and plans to make IPV affordable for developing-country use. |
| doi_str_mv | 10.1093/infdis/jiu128 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1612980629</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>43708866</jstor_id><sourcerecordid>43708866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-41f11b745c1d19d4e2312bf3517e1da2e73c97e566dc8bdd1119bc4caa6f2a423</originalsourceid><addsrcrecordid>eNo90DtPwzAUhmELgWgpjIygjCyhPnbi2GxtxaVSJZC4rJHjS-UqjYudVOLfE5TS6Qzn0Te8CF0Dvgcs6NQ1Vrs43bgOCD9BY8hpkTIG9BSNMSYkBS7ECF3EuMEYZ5QV52hEcgqMMz5G85m1PmhZ1SZZNlK1bi9bo5M3Xzu_d6GLyZdUyjXmIXlvQ_9bOxMT2fQk-HUwMV6iMyvraK4Od4I-nx4_Fi_p6vV5uZitUkUhb9MMLEBVZLkCDUJnhlAglaU5FAa0JKagShQmZ0wrXmkNAKJSmZKSWSIzQifobtjdBf_dmdiWWxeVqWvZGN_FEhgQwTEjoqfpQFXwMQZjy11wWxl-SsDlX7ZyyFYO2Xp_e5juqq3RR_3fqQc3A9jE1ofjP6MF5pwx-gtTBnR8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1612980629</pqid></control><display><type>article</type><title>Affordable Inactivated Poliovirus Vaccine: Strategies and Progress</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Okayasu, Hiromasa ; Sutter, Roland W. ; Jafari, Hamid S. ; Takane, Marina ; Aylward, R. Bruce</creator><creatorcontrib>Okayasu, Hiromasa ; Sutter, Roland W. ; Jafari, Hamid S. ; Takane, Marina ; Aylward, R. Bruce</creatorcontrib><description>After polio eradication is achieved, the use of live-attenuated oral poliovirus vaccine (OPV) must be discontinued because of the inherent risk of the Sabin strains to revert to neurovirulence and reacquire greater transmissibility that could potentially result in the reestablishment of polio transmission. In 2008, the World Health Assembly mandated that the World Health Organization establish a strategy for developing more-affordable inactivated poliovirus vaccine (IPV) options for low-income countries. In 2012, the Strategic Advisory Group of Experts (SAGE) on Immunization recommended universal IPV introduction as a risk-mitigation strategy before the phased cessation of OPV (starting with Sabin type 2) and emphasized the need for affordable IPV options. In 2013, SAGE reiterated the importance of attaining the long-term target price of IPV at approximately $ 0.5 per immunizing dose and encouraged accelerated efforts to develop lower-cost IPV options. This article outlines the 4-pronged approach that is being pursued to develop affordable options and provides an update on the current status and plans to make IPV affordable for developing-country use.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jiu128</identifier><identifier>PMID: 25316868</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Antigens ; Developing Countries ; Disease Eradication - methods ; Dosage ; Drug Discovery - methods ; Humans ; Immune response ; Inactivated poliovirus vaccines ; Influenza vaccines ; Oral poliovirus vaccines ; Poliomyelitis ; Poliomyelitis - immunology ; Poliomyelitis - prevention & control ; Poliovirus ; Poliovirus Vaccine, Inactivated - economics ; Poliovirus Vaccine, Inactivated - immunology ; Poliovirus Vaccine, Inactivated - isolation & purification ; Poliovirus vaccines ; THE POLIO ENDGAME: PREPARING FOR THE POST-ERADICATION ERA ; World Health Organization</subject><ispartof>The Journal of infectious diseases, 2014-11, Vol.210 (suppl_1), p.S459-S464</ispartof><rights>Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c315t-41f11b745c1d19d4e2312bf3517e1da2e73c97e566dc8bdd1119bc4caa6f2a423</citedby><cites>FETCH-LOGICAL-c315t-41f11b745c1d19d4e2312bf3517e1da2e73c97e566dc8bdd1119bc4caa6f2a423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/43708866$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/43708866$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25316868$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okayasu, Hiromasa</creatorcontrib><creatorcontrib>Sutter, Roland W.</creatorcontrib><creatorcontrib>Jafari, Hamid S.</creatorcontrib><creatorcontrib>Takane, Marina</creatorcontrib><creatorcontrib>Aylward, R. Bruce</creatorcontrib><title>Affordable Inactivated Poliovirus Vaccine: Strategies and Progress</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>After polio eradication is achieved, the use of live-attenuated oral poliovirus vaccine (OPV) must be discontinued because of the inherent risk of the Sabin strains to revert to neurovirulence and reacquire greater transmissibility that could potentially result in the reestablishment of polio transmission. In 2008, the World Health Assembly mandated that the World Health Organization establish a strategy for developing more-affordable inactivated poliovirus vaccine (IPV) options for low-income countries. In 2012, the Strategic Advisory Group of Experts (SAGE) on Immunization recommended universal IPV introduction as a risk-mitigation strategy before the phased cessation of OPV (starting with Sabin type 2) and emphasized the need for affordable IPV options. In 2013, SAGE reiterated the importance of attaining the long-term target price of IPV at approximately $ 0.5 per immunizing dose and encouraged accelerated efforts to develop lower-cost IPV options. This article outlines the 4-pronged approach that is being pursued to develop affordable options and provides an update on the current status and plans to make IPV affordable for developing-country use.</description><subject>Antigens</subject><subject>Developing Countries</subject><subject>Disease Eradication - methods</subject><subject>Dosage</subject><subject>Drug Discovery - methods</subject><subject>Humans</subject><subject>Immune response</subject><subject>Inactivated poliovirus vaccines</subject><subject>Influenza vaccines</subject><subject>Oral poliovirus vaccines</subject><subject>Poliomyelitis</subject><subject>Poliomyelitis - immunology</subject><subject>Poliomyelitis - prevention & control</subject><subject>Poliovirus</subject><subject>Poliovirus Vaccine, Inactivated - economics</subject><subject>Poliovirus Vaccine, Inactivated - immunology</subject><subject>Poliovirus Vaccine, Inactivated - isolation & purification</subject><subject>Poliovirus vaccines</subject><subject>THE POLIO ENDGAME: PREPARING FOR THE POST-ERADICATION ERA</subject><subject>World Health Organization</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90DtPwzAUhmELgWgpjIygjCyhPnbi2GxtxaVSJZC4rJHjS-UqjYudVOLfE5TS6Qzn0Te8CF0Dvgcs6NQ1Vrs43bgOCD9BY8hpkTIG9BSNMSYkBS7ECF3EuMEYZ5QV52hEcgqMMz5G85m1PmhZ1SZZNlK1bi9bo5M3Xzu_d6GLyZdUyjXmIXlvQ_9bOxMT2fQk-HUwMV6iMyvraK4Od4I-nx4_Fi_p6vV5uZitUkUhb9MMLEBVZLkCDUJnhlAglaU5FAa0JKagShQmZ0wrXmkNAKJSmZKSWSIzQifobtjdBf_dmdiWWxeVqWvZGN_FEhgQwTEjoqfpQFXwMQZjy11wWxl-SsDlX7ZyyFYO2Xp_e5juqq3RR_3fqQc3A9jE1ofjP6MF5pwx-gtTBnR8</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Okayasu, Hiromasa</creator><creator>Sutter, Roland W.</creator><creator>Jafari, Hamid S.</creator><creator>Takane, Marina</creator><creator>Aylward, R. Bruce</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141101</creationdate><title>Affordable Inactivated Poliovirus Vaccine: Strategies and Progress</title><author>Okayasu, Hiromasa ; Sutter, Roland W. ; Jafari, Hamid S. ; Takane, Marina ; Aylward, R. Bruce</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-41f11b745c1d19d4e2312bf3517e1da2e73c97e566dc8bdd1119bc4caa6f2a423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antigens</topic><topic>Developing Countries</topic><topic>Disease Eradication - methods</topic><topic>Dosage</topic><topic>Drug Discovery - methods</topic><topic>Humans</topic><topic>Immune response</topic><topic>Inactivated poliovirus vaccines</topic><topic>Influenza vaccines</topic><topic>Oral poliovirus vaccines</topic><topic>Poliomyelitis</topic><topic>Poliomyelitis - immunology</topic><topic>Poliomyelitis - prevention & control</topic><topic>Poliovirus</topic><topic>Poliovirus Vaccine, Inactivated - economics</topic><topic>Poliovirus Vaccine, Inactivated - immunology</topic><topic>Poliovirus Vaccine, Inactivated - isolation & purification</topic><topic>Poliovirus vaccines</topic><topic>THE POLIO ENDGAME: PREPARING FOR THE POST-ERADICATION ERA</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okayasu, Hiromasa</creatorcontrib><creatorcontrib>Sutter, Roland W.</creatorcontrib><creatorcontrib>Jafari, Hamid S.</creatorcontrib><creatorcontrib>Takane, Marina</creatorcontrib><creatorcontrib>Aylward, R. Bruce</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okayasu, Hiromasa</au><au>Sutter, Roland W.</au><au>Jafari, Hamid S.</au><au>Takane, Marina</au><au>Aylward, R. Bruce</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Affordable Inactivated Poliovirus Vaccine: Strategies and Progress</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>210</volume><issue>suppl_1</issue><spage>S459</spage><epage>S464</epage><pages>S459-S464</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>After polio eradication is achieved, the use of live-attenuated oral poliovirus vaccine (OPV) must be discontinued because of the inherent risk of the Sabin strains to revert to neurovirulence and reacquire greater transmissibility that could potentially result in the reestablishment of polio transmission. In 2008, the World Health Assembly mandated that the World Health Organization establish a strategy for developing more-affordable inactivated poliovirus vaccine (IPV) options for low-income countries. In 2012, the Strategic Advisory Group of Experts (SAGE) on Immunization recommended universal IPV introduction as a risk-mitigation strategy before the phased cessation of OPV (starting with Sabin type 2) and emphasized the need for affordable IPV options. In 2013, SAGE reiterated the importance of attaining the long-term target price of IPV at approximately $ 0.5 per immunizing dose and encouraged accelerated efforts to develop lower-cost IPV options. This article outlines the 4-pronged approach that is being pursued to develop affordable options and provides an update on the current status and plans to make IPV affordable for developing-country use.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>25316868</pmid><doi>10.1093/infdis/jiu128</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2014-11, Vol.210 (suppl_1), p.S459-S464 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1612980629 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Antigens Developing Countries Disease Eradication - methods Dosage Drug Discovery - methods Humans Immune response Inactivated poliovirus vaccines Influenza vaccines Oral poliovirus vaccines Poliomyelitis Poliomyelitis - immunology Poliomyelitis - prevention & control Poliovirus Poliovirus Vaccine, Inactivated - economics Poliovirus Vaccine, Inactivated - immunology Poliovirus Vaccine, Inactivated - isolation & purification Poliovirus vaccines THE POLIO ENDGAME: PREPARING FOR THE POST-ERADICATION ERA World Health Organization |
| title | Affordable Inactivated Poliovirus Vaccine: Strategies and Progress |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A16%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Affordable%20Inactivated%20Poliovirus%20Vaccine:%20Strategies%20and%20Progress&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Okayasu,%20Hiromasa&rft.date=2014-11-01&rft.volume=210&rft.issue=suppl_1&rft.spage=S459&rft.epage=S464&rft.pages=S459-S464&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jiu128&rft_dat=%3Cjstor_proqu%3E43708866%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1612980629&rft_id=info:pmid/25316868&rft_jstor_id=43708866&rfr_iscdi=true |